{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-273688","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.716665+00:00","generated_at":"2026-05-29T05:14:42.579459+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lyell reports 94% ORR, 71% CR for IMPT-314 in Phase 1-2 large B-cell lymphoma trial","bullets":["Objective response rate 94% (16/17) and complete response rate 71% (12/17) in CAR T-naive patients with ≥2 prior therapies.","No Grade 3+ cytokine release syndrome; Grade 3 ICANS in 13% (3/23) with median resolution time of 5 days.","Median follow-up 6.3 months; 71% of patients remained in response at last follow-up.","Plans to initiate a pivotal trial in 2025 for 3rd-line+ large B-cell lymphoma and continues 2nd-line evaluation.","Final product enriched for naïve/central memory T cells (median 91%), linked to improved overall survival in other studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-273688","json":"https://secwatch.observer/filing/0001193125-24-273688.json","markdown":"https://secwatch.observer/filing/0001193125-24-273688.md","text":"https://secwatch.observer/filing/0001193125-24-273688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/0001193125-24-273688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312524273688/d873794d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:14:42.579459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}